3rd Annual Atlanta Precision Oncology Symposium

 

3rd Annual Atlanta Precision Oncology Symposium
E

2021 Expert Discussion on GU Cancers: Should We Use Olaparib Before or After Chemo for BRCA Patients? How to Deal With Pancreatic Mets? Is It Better to Start With Chemo or Oral Agents for mCRPC?

By 3rd Annual Atlanta Precision Oncology Symposium FEATURING Emmanuel Antonarakis, Daniel Petrylak, Tian Zhang
By 3rd Annual Atlanta Precision Oncology Symposium FEATURING Emmanuel Antonarakis, Daniel Petrylak, Tian Zhang
0 views
February 14, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
Videos
12:36
3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted T…

Feat. H. Borghaei
26:48
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapies for Advanced Urothelial Cancer: Erdafitinib for P…

Feat. D. Petrylak
13:52
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS,…

Feat. H. Borghaei
25:48
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on GU Cancers: Should We Use Olaparib Before …

Feat. E. Antonarakis, D. Petrylak, T. Zhang
26:48
3rd Annual Atlanta Precision Oncology Symposium

Treatment of DNA Repair-Deficient Advanced Prostate Cancer

Feat. E. Antonarakis
26:42
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on Advanced NSCLC: Is Osimertinib a Good Sequ…

Feat. E. Garon, N. Hanna, H. Borghaei, J. Kirkpatrick
23:13
3rd Annual Atlanta Precision Oncology Symposium

Early Detection of Lung Cancer: Molecular Enrichment Strategy

Feat. J. Kirkpatrick
18:36
3rd Annual Atlanta Precision Oncology Symposium

Selecting Systemic First-Line Treatment in Stage IV NSCLC Without Dr…

Feat. N. Hanna
20:20
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on BC: How to Preoperatively Manage TNBC? How…

Feat. I. Mayer, J. Litton, R. O’Regan
32:45
3rd Annual Atlanta Precision Oncology Symposium

2021 Updates on Systemic Therapy for TNBC: Why Should We Choose Neoa…

Feat. R. O’Regan
06:49
3rd Annual Atlanta Precision Oncology Symposium

IO for mTNBC: Overview of the Efficacy Data

Feat. J. Litton
13:30
3rd Annual Atlanta Precision Oncology Symposium

ADCs & Targeted Therapies for Advanced TNBC: Can Sacituzumab Gov…

Feat. J. Litton
09:52
3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Should 1L Therapy Include an EGFR Inhibitor Re…

Feat. E. Garon
15:01
3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Efficacy Data of TKIs in Combination vs. Alone…

Feat. E. Garon
05:55
3rd Annual Atlanta Precision Oncology Symposium

Sequence Algorithm for HER2+ Breast Cancer: Does Neratinib + Cape Ha…

Feat. I. Mayer
05:03
3rd Annual Atlanta Precision Oncology Symposium

CNS Metastases in HER2+ MBC: PFS Data on the Addition of Tucatinib t…

Feat. I. Mayer
17:47
3rd Annual Atlanta Precision Oncology Symposium

HER2+ MBC Sequencing Algorithm: Surveying the Data for Antibody-Drug…

Feat. I. Mayer
14:04
3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Surveying Efficacy Data for I…

Feat. T. Zhang
17:05
3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Assessing IMDC Risk Criteria …

Feat. T. Zhang
08:45
3rd Annual Atlanta Precision Oncology Symposium

Targeting Genetic Mutations in mNSCLC: Clinical Data Overview of RET…

Feat. H. Dilks